Back
 OJIM  Vol.1 No.2 , September 2011
Immunosuppressive therapy in idiopathic multifocal fibrosis. A case report
Abstract: Multifocal fibrosis is a rare condition occurring at any age and characterized by chronic inflammation, soft tissue proliferation and subsequent fibrosis of various vascular connective tissues. Following diagnosis in a 43-year accountant with multiple vascular lesions, the patients was treated successfully with azathioprine and steroids over a period of 3 years. Fatigue and sweating, serologic sign of inflammation and radiological imaging studies normalized completely. Twenty four months after termination of therapy, there were no clinical or serologic signs of relapse.
Cite this paper: nullFranzen, D. , Brochhagen, H. and Benenson, E. (2011) Immunosuppressive therapy in idiopathic multifocal fibrosis. A case report. Open Journal of Internal Medicine, 1, 9-13. doi: 10.4236/ojim.2011.12004.
References

[1]   van Bommel, E.F.H. (2002) Retroperitoneal fibrosis. The Netherlands Journal of Medicine, 60, 231-242.

[2]   Neild, G.H., Rodriguez-Justo, M., Wall, C. and Connolly, J.O. (2006) Hyper-IgG4 disease: Report and characterisation of a new disease. BMC Medicine, 4, 1-25. doi:10.1186/1741-7015-4-23

[3]   Flückiger, B., Bunne, W., Kuhn, M. and Reinhart, W.H. (2006) Idiopathische multifokale Fibrose. Schweiz- erisches Medizinisches Forum, 6, 83-84.

[4]   Szarf, G. and Bluemke, D.A. (2005) Case 83: Multifocal fibrosclerosis with mediastinal-retroperitoneal involve- ment, Radiology, 235, 829-832. doi:10.1148/radiol.2352030088

[5]   Kamisawa, T. and Okamoto, A. (2008) IgG-4 related sclerosing disease. World Journal of Gastroenterology, 14, 3948-3955. doi:10.3748/wjg.14.3948

[6]   Maturen, K.E., Sundaram, B., Marder, W. and Swartz, R.D. (2011) Coronary artery involvement in idiopathic retroperitoneal fibrosis: Computed tomographic findings. Journal of Thoracic Imaging, (Epub ahead of print).

[7]   Novak, I., Moravek, P., Base, J. and Svab, J. (1994) Longterm results in patients with retroperitoneal fibrosis. Rozhledy v Chirurgii, 73, 287-290.

[8]   Kardar, A.H., Kattan, S., Lindstedt, E. and Hanash, K. (2002) Steroid therapy for idiopathic retroperitoneal fibrosis: Dose and duration. Journal of Urology, 168, 550- 555. doi:10.1016/S0022-5347(05)64677-0

[9]   Warnatz, K., Keskin, A.G., Uhl, M., Scholz, C., Katzenwadel, A., Vaith, P., Peter, H.H. and Walker, U.A. (2005) Immunosuppressive treatment of chronic periaortitis: A retrospective study of 20 patients with chronic periaortitis and a review of the literature. Annals of the Rheumatic Diseases, 64, 828-833. doi:10.1136/ard.2004.029793

[10]   Vaglio, A. (2006) Retroperitoneal fibrosis. The Lancet, 367, 241-251.

[11]   Vaglio, A., Greco, P., Conradi, D., Palmisano, A., Martorana, D., Ronda, N. and Buzio, C. (2006) Autoimmune aspects of chronic periarotitis. Autoimmunity Reviews, 5, 458-464. doi:10.1016/j.autrev.2006.03.011

[12]   Swartz, R.D. (2009) Idiopathic retroperitoneal fibrosis: A review of the pathogenesis and approaches to treatment. American Journal of Kidney Diseases, 54, 546-553. doi:10.1053/j.ajkd.2009.04.019

[13]   Swartz, R.D., Lake, A.M., Roberts, W.W., Faerber, G.J. and Wolf, J.S. (2008) Idiopathic retroperitoneal fibrosis: A role for mycophenolate motefil. Clinical Nephrology, 69, 260-268.

[14]   Paz, Z. and Shoenfeld, Y. (2010) Antifibrosis: To reverse the Irreversible. Clinical Reviews in Allergy and Immunology, 38, 276-286. doi:10.1007/s12016-009-8157-7

 
 
Top